NCT06912165View on ClinicalTrials.gov

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

November 30, 2025

Conditions
Brief Description of Focus of Study
Interventions
DRUG

WD-890 tablet

Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG

WD-890 tablet

Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG

WD-890 tablet

Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

DRUG

Placebo

Participants will receive placebo QD from Week 0 through Week 16.

Trial Locations (1)

210000

RECRUITING

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing

All Listed Sponsors
lead

Zhejiang Wenda Medical Technology Co., Ltd.

OTHER